Therapeutic
drug delivery microrobots capable of accurate targeting
using an electromagnetic actuation (EMA) system are being developed.
However, these drug delivery microrobots include a large number of
magnetic nanoparticles (MNPs) for accurate EMA targeting, which causes
side effects, such as problems with membrane integrity and normal
cell apoptosis. Here, a biocompatible and hydrolyzable PEGDA-based
drug delivery helical microrobot capable of MNP retrieval is proposed
in which doxorubicin (DOX), an anticancer drug, is encapsulated and
MNPs are conjugated by a disulfide bond. After being accurately delivered
to the lesion of cancer cells through magnetic field manipulation,
the fabricated microrobot provides rapid MNP separation and retrieval
from the microrobot because of the use of dithiothreitol (DTT), a
reducing agent, as an environment similar to the surrounding cancer
cells and near-infrared (NIR) as an external stimulus. The characteristics
of the fabricated microrobot are analyzed, and fundamental tests for
active electromagnetic field manipulation, separation/retrieval of
MNPs from the microrobot, and its hydrolysis are discussed. The therapeutic
performance of the fabricated microrobot is verified through an in vitro test using tumor cells. Consequently, by use of
an integrated system of microscope, eight-coil EMA, and NIR it is
shown that the proposed microrobot can be moved to the target site
by electromagnetic manipulation. The MNPs conjugated to the microrobot
can be separated and retrieved, and the therapeutic effect on tumor
cells by the encapsulated drug can be seen.